Focused On-demand Library for Conserved oligomeric Golgi complex subunit 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q8WTW3

UPID:

COG1_HUMAN

Alternative names:

Component of oligomeric Golgi complex 1

Alternative UPACC:

Q8WTW3; Q9NPV9; Q9P2G6

Background:

The Conserved oligomeric Golgi complex subunit 1, also known as Component of oligomeric Golgi complex 1, plays a pivotal role in maintaining normal Golgi function. This protein is essential for the proper processing and sorting of proteins, ensuring they are correctly glycosylated and directed to their destination within the cell. Glycosylation, a critical post-translational modification, is crucial for protein stability, signaling, and cell-cell interactions.

Therapeutic significance:

Given its involvement in Congenital disorder of glycosylation 2G (CDG2G), a multisystem disorder characterized by defects in glycoprotein biosynthesis leading to a wide array of clinical features, understanding the role of Conserved oligomeric Golgi complex subunit 1 could open doors to potential therapeutic strategies. Targeting the underlying glycosylation defects presents a promising avenue for treating CDG2G and improving patient outcomes.